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Abstract
Problem: The T-cell immunoglobulin and mucin domain (TIM) family is a relatively newly described group of molecules with
a conserved structure and important immunological functions. Identification of Galectin-9 as a ligand for TIM-3 has
established the Galectin-9/TIM-3 pathway as an important negative regulator of Th1 immunity and tolerance induction.
Data about the TIM-3/Gal-9 pathway in the pathogenesis of human diseases is emerging, but their possible role during
human pregnancy is not precisely known. The aim of our study was to investigate the number, phenotype and functional
activity of TIM-3+ peripheral blood mononuclear cells during healthy human pregnancy.
Methods of Study: 57 healthy pregnant women [first trimester (n = 16); second trimester (n = 19); third trimester (n = 22)]
and 30 non-pregnant controls were enrolled in the study. We measured the surface expression of TIM-3 by cytotoxic T cells,
NK cells and NK cell subsets as well as Galectin-9 expression by regulatory T cells by flow cytometry. We analyzed the
cytokine production and cytotoxicity of TIM3+ and TIM3- CD8 T and NK cells obtained from non-pregnant and healthy
pregnant women at different stages of pregnancy by flow cytometry. Serum Galectin-9 levels were measured by ELISA.
Results: Our results show that the numbers of peripheral NK and cytotoxic T cells and their TIM-3 expression do not change
between the first, second and third trimesters of pregnancy. Compared to non-pregnant individuals, regulatory T cells show
higher level of Galectin-9 expression as pregnancy proceeds, which is in line with the level of Galectin-9 in the patients sera.
Cytotoxic T cells, NK cells and NK cell subsets expressing TIM-3 molecule show altered cytokine production and cytotoxicity
during pregnancy compared to non-pregnant individuals.
Conclusion: Our results indicate that Galectin-9 expressing regulatory T cells, TIM-3+ cytotoxic T cells and NK cells could
play an important role in the maintenance of healthy pregnancy.
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Introduction
During healthy pregnancy, the maternal immune system has to
be altered to enable survival of the semi-allogeneic fetus.
Pregnancy is an ideal condition to study active immunotolerance.
During pregnancy the fetus will not be attacked or rejected by the
maternal immune system but rather successfully accepted by the
mother. Precise immunoregulation of the maternal immune
system is critical for normal pregnancy and fetal development.
For many years Th1/Th2 hypothesis has provided a useful
framework for studies of the immunology of pregnancy. However,
the findings that pregnancy itself is an inflammatory state has led
to a revision of this hypothesis and now it is apparent that both
arms of the immune response are intensified during healthy
pregnancy, but with a stronger bias towards Th2 than Th1
responses [1–3]. The participation of NK and NKT cells in the
Th1/Th2 shifts of pregnancy suggests a dominant role of the
innate rather than the adaptive immune system [4]. The Th1/Th2
paradigm has recently been reconstituted to include a third
population of T helper cells that produce IL-17, therefore these
cells are designated as Th17 cells [5]. This Th2 cytokine
polarization occurs both at systemic level and at the fetal-maternal
interface, [6] and the cause behind this cytokine shift are not
clearly defined.
Pregnancy as a physiological condition includes the altered ratio
and function of different lymphocytes subpopulations compared to
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non-pregnant status. Therefore it is important to investigate and
understand the immune regulatory mechanism behind these
immunological changes.
The immunoglobulin superfamily member T-cell immunoglob-
ulin mucin 3 (TIM-3) was first discovered in 2002 on interferon
IFN-c producing CD4+ (Th1) and on CD8+ T cytotoxic cells (Tc)
[7]. TIM-3 expression was verified in a variety of immune cells,
including Th1, Th17, NK cells, NKT cells, Tregs, and also on
antigen presenting immune cells such as dendritic cells and
monocytes [8]. TIM-3 molecule has been implicated in both
activation and inhibition of immune responses [9,10], but its in vivo
function have remained unknown. Expression of TIM-3 on Th1
cells provides a key checkpoint that serves to dampen proin-
flammatory Th1-dependent T-cell responses and may contribute
to the maintenance of pregnancy. In line with this, Chabtini et al.
examined the TIM-3-expression on innate immune cells by using
an allogeneic mouse model of pregnancy and indicated their
possible role in the regulation of tolerance at the fetomaternal
interface [11]. The only human study presented that TIM-3 is up-
regulated by monocytes in peripheral blood of pregnant women
indicate that abnormal TIM-3 expression might be related to the
loss of pregnancy [8].
Galectin-9 (Gal-9) is a member of a family of evolutionary
conversed endogenous lectins and is characterized by the presence
of two carbonhydrate recognition domains with affinity for b-
galactoside [12]. Many studies examined the role of Gal-9 in
immunological contexts, which can influence the immune system
in different ways, either by exacerbating the inflammatory process
[13] or by acting as an anti-inflammatory agent [14].
Among several identified receptors of Gal-9, TIM-3 has been
studied most extensively. There is evidence that engagement of
TIM-3 by its ligand Gal-9 leads to the death of Th1 and Th17
cells, furthermore influences the ability to induce T cell tolerance
in both mice and humans [15–17]. Thus, engagement of TIM-3
by Gal-9 may function as a negative regulator, abrogating Th1-
and Th17 driven immune responses and may modulate the Th1/
Th2 balance.
Recently, human Gal-9+ Th cells were identified expressing
Gal-9 on their surface and secreting Gal-9 upon TCR stimulation
resulting in the regulation of Th17/Treg development [18].
Moreover it was shown that IL-6 abrogates the increase of Gal-9+
Th cells in vitro, and indicates that neutralization of IL-6 may be a
strategy for increasing Gal-9+ Th cells in order to ameliorate Th1/
Th17-skewed immunity.
Supporting a reproductive role for Gal-9, M von Wolff et al.
and Popovici et al. found that human endometrium and decidua
express Gal-9 and it’s strong expression suggest a potential role
during implantation [19–21]. In this regard, it is possible that
TIM-3/Gal-9 interaction could play an important role in the
regulation of maternal immune tolerance toward the fetus and
may be a potent regulator of the adaptive and innate immune
responses. Although data about the TIM-3/Gal-9 pathway in the
pathogenesis of human diseases is emerging their possible role
during human pregnancy is not precisely known.
Therefore our aim was to investigate the expression of TIM-3
and Gal-9 on different T and NK cell subsets throughout
pregnancy and in non-pregnant women, and to determine the
pregnancy related phenotypic changes of peripheral blood
mononuclear cells. We suppose that their interaction plays a
significant role in maintenance of healthy pregnancy.
Materials and Methods
Patients
To study Gal-9 and TIM-3 expression throughout pregnancy,
16 healthy women were recruited in the first trimester, 19 in the
second, 22 in the third trimester and 30 non-pregnant healthy
women were included in this study (Table I). None of the women
had any significant medical history, current or recent illnesses, or
were taking medications.
Ethics statement
Written informed consent was obtained from all participants.
The study protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki as reflected in a priori approval by the
Regional Ethical Committee at the Faculty of Medicine,
University of Pe´cs.
Lymphocyte separation, cryopreservation and thawing
Peripheral blood mononuclear cells (PBMC) were isolated from
heparinized venous blood on Ficoll-Paque gradient (GE Health-
care Life Sciences, USA). After washing in RPMI 1640 medium
(Lonza, Switzerland) the cells were counted centrifuged and
resuspended in human AB serum (Lonza, Switzerland) containing
10% DMSO for cryoprotection. Cells were aliquoted in cryovials
and stored in a –80uC mechanical freezer. Thawing was carried
out on the day of fluorescent cell labeling as quickly as possible in
37uC water bath and DMSO (Sigma-Aldrich, Hungary) was
washed out twice in RPMI 1640 medium.
Antibodies
Freshly thawed PBMC were used for surface and intracellular
staining and analysis. The following monoclonal antibodies were
used: fluorescein isothiocyanate (FITC)-conjugated anti-human
Table 1. Characteristics of Non-pregnant, 1st, 2nd and 3rd trimester pregnant women.
Non-pregnant 1st trimester 2nd trimester 3rd trimester
No. of patients 30 16 19 22
Age (years) 33 (19–44) 31 (27–35) 32 (26–45) 33 (28–43)
Gestation age at sampling
(weeks)
- 12 (11–16) 26 (24–28) 36 (35–38)
Gestation age at birth
(weeks)
- 38,8 (35–41) 38,0 (33–41) 39,0 (37–41)
Gravidity 1,5 1,2 1,9 1,7
Parity 1,0 0,4 0,7 0,5
Data are shown as mean (range). Statistical comparisons were made by using the ANOVA tests. Results did not differ significantly between study groups.
doi:10.1371/journal.pone.0092371.t001
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CD3 (BD Pharmingen, USA), FITC-conjugated anti-human CD4
(BD Pharmingen, USA), FITC-conjugated anti-human CD8 (BD
Pharmingen, USA), FITC-conjugated anti-human CD107a (BD
Pharmingen, USA), phycoerythrin (PE)-conjugated anti-human
Galectin-9 (Biolegend, USA), PE-conjugated anti-human TIM-3 (R
and D Systems, USA), allophycocyanin (APC)-conjugated anti-
human CD56 (BD Pharmingen, USA), APC-conjugated anti-
human CD8 (BD Pharmingen, USA), APC-conjugated anti-human
TIM-3 (R and D Systems, USA) APC-conjugated anti-human
FoxP3 (eBioscience, USA). Control antibodies included isotype-
matched FITC-conjugated, PE-conjugated and APC-conjugated
mouse antibodies (all from BD-Pharmingen, USA).
Labeling of lymphocytes and flow cytometric analysis
Cryopreserved cells were quickly thawed and washed with PBS
(Lonza, Switzerland) to remove DMSO. 106 PBMC in 100 ml
PBS/tube was incubated for 30 minutes at room temperature with
the fluorochrome-labeled monoclonal antibodies. After washing,
the cells were resuspended in 300 ml PBS containing 1%
paraformaldehyde, and stored at 4uC in dark until FACS analysis.
Labeled cells were analyzed with a FACSCalibur flow cytometer
(BD Immunocytometry Systems, Erembodegen, Belgium)
equipped with the CellQuest software program (BD Biosciences,
San Diego, CA, USA) for data acquisition and analysis.
CD107a cytotoxicity assay
To determine CD107a surface expression by cytotoxic T cells
and NK cells, PBMC were incubated for 4 h at 37uC in an
atmosphere containing 5% CO2 in the presence of FITC-
conjugated anti-human CD107a monoclonal antibody in RPMI
1640 medium containing 10% fetal bovine serum, penicillin and
streptomycin (Lonza, Switzerland), ionomycin (Sigma–Aldrich,
Hungary) and phorbol myristate acetate (Sigma–Aldrich, Hun-
gary). After stimulation the cells were washed and resuspended in
PBS then stained with antibodies to Tc cell and NK cell markers
(APC-conjugated anti-human CD8 or APC-conjugated anti-
human CD56) together with PE-conjugated anti-human TIM-3
antibody for 30 min at room temperature. The cells were washed
in PBS, fixed with 1% paraformaldehyde and evaluated by
FACSCalibur flow cytometer (BD Immunocytometry Systems,
Erembodegen, Belgium) equipped with the CellQuest software
program (BD Biosciences, San Diego, CA, USA) for data
acquisition and analysis..
FoxP3 staining
After surface labeling intracellular staining of FoxP3 was
performed using the FoxP3 Staining Buffer Set (eBioscience,
USA) according to the manufacture’s protocol. Briefly, cells were
permeabilized in 1 ml fixation/permeabilization buffer (Concen-
trate/Diluent 1:4) at 4uC for 1 h. Then the samples were washed
twice in buffer and stained with the APC-conjugated anti-human
FoxP3 monoclonal antibody at 4uC for 1 hour. Flow cytometric
analysis was performed on FACSCalibur flow cytometer (BD
Immunocytometry Systems, Erembodegen, Belgium) equipped
with the CellQuest software program (BD Biosciences, San Diego,
CA, USA) for data acquisition and analysis.
MACS separation
PBMC were separated from heparinized venous blood on
Ficoll-Paque gradient. For the MACS separation, up to 26108
total cell were centrifuged at 1500 rpm for 10 min in cold MACS
buffer (PBS with 5% FCS). The samples were resuspended in 2ml
cold MACS buffer then applied to pre-separation filters to remove
cell clumps and centrifuged at 1500 rpm for 10 min in cold MACS
buffer. Magnetic bead-conjugated anti-human CD56 antibody
(MACS, Miltenyi Biotech, Germany) (20 ml/107 cell) was used to
label NK cells for 15 min on ice. After labeling the cell suspensions
were centrifuged at 1200 rpm for 10 min in cold MACS buffer.
Labeled cells were resuspended in 500 ml of cold MACS buffer
and put a magnetic separation (MS) column (Miltenyi Biotec,
Germany), which was freshly equilibrated with 500 ml cold MACS
buffer. Unlabeled CD562 cells passed through the column,
whereas the CD56+ cells remained in the column due to the
magnetic field. After triple washing with 500 ml of cold MACS
buffer, the column was removed from the magnetic field and the
CD56+ fraction were eluted with 1 ml cold MACS buffer using a
plunger. The unlabeled cell fractions (CD562) were centrifuged at
1500 rpm for 10 min, resuspended in an appropriate volume of
cold MACS buffer and labeled with a human CD8 (MACS,
Miltenyi Biotech, Germany) magnetic bead-conjugated antibody
(20 ml/107) cell.
The separated CD56+ and CD8+ cells were washed with PBS
at 1500 rpm for 10 min. The CD56+ cell pellets were then
incubated with of FITC-conjugated anti-human CD3, PE-
conjugated anti-human TIM-3 and APC-conjugated anti-human
CD56 for 30 min at room temperature in dark. The CD8+ cell
pellets were incubated with PE-conjugated anti-human TIM-3
and APC-conjugated anti-human CD8 for 30 min at room
temperature in dark. The cells were washed with PBS at 2000 rpm
for 5 min and resuspended in 400 ml PBS for sorting.
Cell sorting
The MACS separated and labelled cells were sorted using a BD
FACS ARIA II with a BD FACS Diva V6 software (BD
Biosciences, USA). NK cells and CD8 cells were recognized
based on scatter characteristics and expression of different
markers. CD3-TIM-3-CD56dim, CD3-TIM-3+CD56dim CD3-
TIM-3-CD56bright, CD3-TIM-3+CD56bright, CD8+TIM-3-
and CD8+TIM-3+ cells were separated. After sorting, the purity
of the cell fraction was measured on the BD FACS ARIA (BD
Immunocytometry Systems, Erembodegen, Belgium) equipped
with a 70 mm nozzle. Purity was greater than 95%.
Sorted cells were collected in 300 ml RPMI 1640 medium
containing 10% fetal bovine serum. After sorting the cells were
washed with PBS and centrifuged at 1500 rpm for 10 min. The
supernatants were aspirated then the remaining cells were
incubated overnight at 37uC in the presence of RPMI 1640
medium containing 10% fetal bovine serum, penicillin and
streptomycin (Lonza, Switzerland), ionomycin (Sigma–Aldrich,
Hungary) and phorbol myristate acetate (Sigma–Aldrich). After
stimulation the cells were centrifuged at 2000 rpm for 10 minutes.
The supernatants were collected, aliquoted and stored at –80uC in
a mechanical freezer for further cytokine analysis.
Cytometric Bead Array (CBA)
Concentration of cytokines from supernatants were determined
using a Human Th1/Th2/Th17 CBA kit (BD Biosciences, USA)
which allowed for the simultaneous detection of IL-2, IL-4, IL-6,
IL-10, TNF-a, IFN-c and IL-17A. Aliquoted samples were thawed
and CBA analysis performed according to the manufacturer’s
protocol. Briefly, beads coated with capture antibodies were
mixed. 50 ml of the capture bead mixture was added to 50 ml of
sample. To these sample-bead compounds, 50 ml of phycoerythrin
conjugated detection antibody was added and this mixture was
incubated for 3 h in dark at room temperature. The samples then
were washed with 1 ml of wash buffer at 1100 rpm for 5 min and
the pellets were resuspended in 300 ml wash buffer. Cytokine
TIM-3/Galectin-9 Pathway during Pregnancy
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standards were serially diluted to facilitate the construction of
calibration curves necessary for determining protein concentra-
tions of test samples. Flow cytometric analysis was performed on a
BD FACSCanto II (BD Immunocytometry Systems, Erembode-
gen, Belgium) with BD FACS DIVA software V6 and data were
analyzed with FCS Express V3 software.
Galectin-9 ELISA
Serum samples were collected from healthy non-pregnant
individuals and from the 1st, the 2nd and the 3rd trimester group
of gestation. 10ml venous blood was taken to disposable sterile test
tube and centrifuged at 2000 rpm for 10 minutes. Serum samples
then transferred in 1ml aliquots into cryovials and stored frozen at
–80uC until analysis.
Serum Gal-9 levels were measured by ELISA in 26 non-
pregnant women and in 10 healthy women in each trimester of
pregnancy.
The serum Gal-9 concentration was determined by a quanti-
tative sandwich enzyme immunoassay according to the manufac-
turer’s protocol (BLUEGENE GAL9 ELISA kit, AMS Biotech-
nology, UK). Briefly, 50 ml/well of standard and human serum
samples obtained from healthy pregnant woman and normal
controls were added to 96 well microplate pre-coated with
monoclonal antibody specific for Gal-9 protein. Then 100 ml of
enzyme conjugate (horseradish peroxidase-conjugated polyclonal
anti-Gal-9) was added to each well, mixed thoroughly and
incubated for 1 hour at 37uC. Then the wells of the microtiter
plate were washed 5 times with 200 ml of Wash buffer. For color
development 50 ml of Substrate A and 50 ml of Substrate B were
added to each well, and incubated for 10–15 minutes at 37uC in
the dark. Finally 50 ml/well of Stop solution was added to the wells
and mixed with gentle tapping to terminate the reaction. The
optical density was measured at 450nm with FluoSTAR Optima
(BMG Labtech, Germany) microplate spectrophotometer and the
Gal-9 protein concentration was determined with Optima 2.10 R2
built-in data calculator software.
Statistical analysis
Statistical analysis was performed using statistical software SPSS
version 20. package. Multiple comparisons were made using one-
way ANOVA with Bonferroni correction. Differences were
considered significant if the p value was equal to or less than 0.05.
Results
1. Phenotype analysis of peripheral blood mononuclear
cells throughout pregnancy and in non-pregnant
women.
We investigated the percentage of CD3+ T cells, CD4+, CD8+
T cell subpopulations, NK cells, NKT cells and Gal-9+ Th cells in
the peripheral blood of normal pregnant women during each
trimester of pregnancy and in non-pregnant women.
In this study investigating healthy pregnant women, CD3+,
CD4+, CD8+ T cell, NKT cells, NK cell and NK subpopulation
levels were not significantly changed during first, second and third
trimester even to compared to non-pregnant women. The
frequency of NK cells and CD56dim NK cells throughout
pregnancy was lower and the frequency of CD56bright cells was
higher than in non-pregnant women but these results did not
reach the level of significance (Table II).
Gal-9 staining revealed the existence of surface Gal-9-expressing
CD4 T cells (Gal-9+ Th cells) [18]. The frequency of these cells
were approximately 1% in non-pregnant women and we detected
an increased frequency throughout pregnancy reaching 2,39 % in
the third trimester (Table II). The frequency of Gal-9 Th cells in the
third trimester was significantly higher than in non-pregnant
women, as well as women in the first and second trimester (Table II).
2. Differential TIM-3 expression by peripheral blood
mononuclear cell subsets throughout pregnancy and in
non-pregnant women.
We measured the surface expression of TIM-3 by Th cells, Tc
cells, NK cells, NK cell subsets and NKT cells by flow cytometry.
TIM-3 expression by the CD4 T cells showed no significant
difference between any investigated groups (Fig. 1A). Investigating
TIM-3 expression by CD8+ T cells we found a decrease in the 2nd
trimester compared to other trimesters and to the samples from
the non-pregnant group, however this change did not reach the
level of statistical significance (Fig. 1A). Furthermore TIM-3
Table 2. Peripheral blood mononuclear cell phenotype characteristics throughout pregnancy and in non-pregnant women.
Non-pregnant 1st trimester 2nd trimester 3rd trimester P-value
CD3+ T cells 66,6462,23 65,1063,27 69,4363,33 67,7461,34 NS
CD4+ T cells 44,0462,32 39,9262,28 45,6863,47 39,0362,60 NS
CD8+ T cells 32,0261,51 35,2561,53 28,9862,67 34,3162,41 NS
CD8+ TIM-3+ T cells 5,5960,83 6,060,89 4,3660,88 5,9760,50 NS
CD3- CD56+ cells 13,6561,38 12,3161,85 10,6961,74 11,4761,53 NS
CD3- CD56dim cells 12,7261,31 10,5661,75 9,2961,69 9,7461,39 NS
CD3- CD56bright cells 1,0360,24 1,8060,29 1,4460,30 1,7660,24 NS
CD3- CD56+ TIM-3+ cells 9,6161,41 9,1661,53 7,3461,30 9,0561,30 NS
CD3- CD56dim TIM-3+ cells 9,0261,38 8,1061,42 6,4961,25 8,0761,23 NS
CD3- CD56bright TIM-3+ 0,6160,18 1,1160,22 0,9360,24 1,1160,17 NS
CD3+ CD56+ cells 4,0860,75 6,3761,21 4,7060,98 5,4661,26 NS
Gal-9+ Th cells 0,9760,13 0,6660,09 1,1760,3 2,3960,49 3rd vs. NP p,0,01 3rd vs. 1st
p,0,01 3rd vs. 2nd p,0,03
Statistical comparisons were made by using the ANOVA tests. The results were expressed as the mean value6standard error of the mean (SEM). Differences were
considered significant when the value of p was equal to or less than 0.05. NS = not statistically significant.
doi:10.1371/journal.pone.0092371.t002
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expression was significantly increased by NK cells in samples from
the 3rd trimester compared to the samples in the 2nd trimester
(65,9162,91 vs. 78,0762,23) (Fig. 1B). Analyzing the NK cell
subsets, the TIM-3 expression by CD56dim NK cells was
significantly increased in samples from the third trimester compared
to the samples from the second trimester and from non-pregnant
women (66,0163,20 vs. 79,9762,29; 67,1863,88 vs. 79,9762,29).
In the case of CD56bright cells we only found an increasing
tendency during the three trimesters compared to non-pregnant
women, but these results were not statistically significant (Fig. 1B).
TIM-3 expression by NKT cells did not show any significant
difference between any investigated groups (data not shown).
3. Downregulation of proinflammatory cytokine
production by peripheral CD8+ T, CD56dim and
CD56bright NK cells expressing TIM-3.
Th1, Th2 and Th17 cytokines were analyzed by CBA system,
where IL-4, IL-6 and IL-1 cytokines were under the detectable
level.
CD8+ T cells expressing TIM-3 produced significantly lower
level of proinflammatory (IL-2, TNF-a and IFN-c) and Th17
cytokines compared to TIM-3 negative counterparts in the first
and third trimester of pregnancy and in healthy non-pregnant
controls (Table III).
IL-2 cytokine production by TIM-3 positive CD56dim NK cells
was significantly lower compared to TIM-3 negative CD56dim
NK cells in the first and second trimester of pregnancy (Table III).
In the second trimester of pregnancy IFN-c cytokine production
by TIM-3 positive CD56bright NK cells was significantly higher
compared to TIM-3 negative CD56bright NK cells (Table III).
4. Altered cytotoxic activity of TIM-3 expressing
peripheral CD8+ T cells, NK cells and NK cell subsets
throughout pregnancy and in non-pregnant women.
Investigating the cytotoxic activity of TIM-3+ CD8+ Tc cells
during pregnancy, we found that CD107a expression was
significantly higher in samples from 3rd trimester compared to
1st and 2nd trimester and non-pregnant women (6,3261,19 vs.
Figure 1. TIM-3 expression by peripheral blood mononuclear cell subsets throughout pregnancy and in non-pregnant women. The
expression of TIM-3 by Th cells, Tc cells, NK cells and NK cell subsets in the peripheral blood of normal pregnant women during each trimester of
pregnancy and in non-pregnant women. The solid bars represent medians, the boxes indicate the interquartile ranges and the lines show the most
extreme observations. Differences were considered statistically significant for P-values #0.05.
doi:10.1371/journal.pone.0092371.g001
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2,2260,50; 6,3261,19 vs. 2,3260,46; 6,3261,19 vs. 2,1160,86)
(Fig. 2A). CD8+ T cells expressing TIM-3 in the third trimester of
pregnancy showed significantly increased CD107a expression
compared to TIM-3 negative CD8+ T cells (Fig. 2A).
Furthermore TIM-3 positive NK cells and NKdim subset
showed similar CD107a expression pattern, where the cytotoxic
activity was significantly increased in samples from 3rd trimester
compared to the non-pregnant group and 1st trimester group (NK
cells: 3,8361,27 vs. 17,3863,29; 5,1161,17 vs. 17,3863,29 (Fig.
2B); NKdim cells: 3,7661,23 vs. 15,7363,19; 4,6961,07 vs.
15,7363,19 (Fig. 3A)). Analyzing CD107a expression by the
NKbright subpopulation showed no significant differences (Fig.
3B). Interestingly cytotoxic activity of TIM-3 positive NK cell and
NKdim cell were significantly lower in non-pregnant women and
in all trimesters compared to TIM-3 negative counterparts (Fig. 2B
and 3A).
5. Circulating Galectin-9 levels throughout pregnancy
and in non-pregnant women
Serum Galectin-9 levels differ significantly between non-
pregnant and healthy pregnant women in each trimester (Fig. 4).
Analyzing Gal-9 levels throughout pregnancy we found an
increasing tendency with a significant elevation of serum Gal-9
concentration in the second and third trimester compared to the
first trimester (Fig. 4).
Discussion
The maternal immune system undergoes profound transforma-
tion as early as the beginning of pregnancy. These prominent
changes are directed to protect the fetus from a detrimental
immune response.
Widely distributed across the cells of innate and adaptive
immune system and in nonmyeloid cell lineages, TIM family
members are emerging as central modulators of numerous facets
of the immune response. Much remains to be understood
regarding the pleiotropic role of TIM-3 molecule in reproductive
immunology.
Current thinking suggests that Galectin-9 is immunomodulatory
to TIM-3 positive cells. This alters the production of cytokines,
leads to the death of Th1 cells and selective loss of IFN-c
production by T cells, and furthermore influences the ability to
induce T cell tolerance [17,22].
We found that CD8+ T cells expressing TIM-3 produced
significantly lower level of proinflammatory and Th17 cytokines
compared to TIM-3 negative counterparts in the first and third
trimester of pregnancy and in healthy non-pregnant controls, we
suppose that Gal-9 inhibits proinflamamtory cytokine production
through TIM-3 receptor activation downregulating Th1 and Th17
response. Based on our results we hypothesize that during
pregnancy Gal-9 has the potential to control the cytokine
production of TIM-3 positive CD8+ T cells favoring the
establishment of Th2 dominance.
On the other hand we showed that the frequency and cytotoxic
activity of CD8+ T cells expressing TIM-3 in the peripheral blood
of pregnant women remained constant during the first and second
trimester and their proinflammatory cytokine production was
significantly decreased in the first trimester compared to TIM-3
negative counterparts. We suggest that TIM-3 expressing CD8+ T
cells, while providing immune protection against invading
pathogens, could be involved in the establishment and mainte-
nance of healthy pregnancy via the production of cytokines during
the first two trimesters.
In contrast to this observation TIM-3 positive CD8+ T cells in
the third trimester were enriched in the peripheral blood
compared to the first and second trimester. Although they
produced less proinflammatory cytokines than TIM-3 negative
CD8+ T cells they showed increased cytotoxic activity. These
Table 3. Cytokine production by TIM-3 positive and negative CD8+ T, CD56dim and CD56bright NK cells.
Non-pregnant 1st trimester 2nd trimester 3rd trimester
pg/ml TIM-3+ TIM-3- p TIM-3+ TIM-3- p TIM-3+ TIM-3- p TIM-3+ TIM-3- p
CD56 IL-2 9,18 117,18 NS 9,53 62,95 ,0,04 9,25 17,17 ,0,01 9,23 80,71 NS
dim TNF-a 1625,01 2157,81 NS 1820,63 2278,48 NS 104,75** 793,57 NS 439,75** 403,62 NS
cells IFN-c 2010,29 2172,1 NS 3095,85 3516,78 NS 218,03** 1095,87 NS 816,23*** 696,77
$ NS
IL-17 ,min ,min NS ,min ,min NS ,min ,min NS ,min ,min NS
CD56 IL-2 20,97 114,27 NS 13,25 39,99 NS 14 12,78 NS 12,93 50,89 NS
dim TNF-a 1211,37 1786,06 NS 1036,76 1315,13 NS 641,82 461,83 NS 1188,97 1046,67 NS
cells IFN-c 1961,81 3513,19 NS 2656,23 2543,13 NS 1632,29 979,18 ,0,04 1894,9 2136,18 NS
IL-17 ,min ,min NS ,min ,min NS ,min ,min NS ,min ,min NS
IL-2 3076,06 6400,32 ,0,05 2463,73 7812,88 ,0,01 687,87 1276,9* NS 2587,58 7471,57 ,0,03
CD8 TNF-a 1385,92 6064,46 ,0,01 1217,89 6654,4 ,0,01 356,7 1468,89
$ NS 861,61 3427,65 ,0,01
T cells IFN-c 3455,09 5750,34 NS 4223,87 6306,06 ,0,05 908,5
$$$
2093
$$ NS 2364,49 4851,96 ,0,04
IL-17 17,33 345,2 ,0,04 16,93 247,9 ,0,05 9,83 11,49 NS 20,83 257,01 ,0,04
Statistical comparisons were made by using the ANOVA tests. The results were expressed as the mean value. Differences were considered significant when the value of
p was equal to or less than 0.05. NS = not statistically significant.
*Sig. from NP;1st; 3rd (p,0,01).
**Sig. from NP;1st (p,0,01).
***Sig. from NP (p,0,05);1st (p,0,01).
$Sig. from 1st (p,0,01).
$$Sig. from 1st (p,0,04).
$$$Sig. from NP (p,0,03);1st (p,0,05).
doi:10.1371/journal.pone.0092371.t003
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observations let us hypothesize that these cells could play a role in
the physiological processes leading to the initiation of labor.
The systemic regulation of NK cells is essential for the
achievement of successful reproductive outcome [23]. In line with
many publications, peripheral blood NK cell levels were found not
to be significantly changed throughout pregnancy, also as
compared to non-pregnant controls [24].
NK cell parameters, either in absolute numbers or in
proportion, subsets, functional activity such as cytotoxicity or
secretory cytokine profile, receptor or gene expression, have been
extensively investigated in peripheral, endometrial or decidual NK
cells, but our study is the first to investigate TIM-3 expressing NK
cells in peripheral blood prior to and throughout pregnancy.
We found that TIM-3 receptor expression by NK and cytotoxic
NKdim cells was significantly increased in the third trimester when
compared to the second trimester. In the case of NKbright cells we
found no differences.
Investigating Th1, Th2 and Th17 cytokine production by NK
cells and its subsets we did not find any characteristic differences
between TIM-3 positive and negative counterparts in the case of
Th2 and Th17 cytokines. Investigating Th1 cytokines we found
that IL-2 production by TIM-3 positive CD56dim NK cells was
significantly lower compared to TIM-3 negative CD56dim NK
cells in the first and second trimester of pregnancy. IFN-c
production by TIM-3 positive CD56bright NK cells was
significantly higher compared to TIM-3 negative CD56bright
NK cells in the second trimester of pregnancy.
The interaction between soluble or membrane bound Gal-9 and
TIM-3 positive NK cells could explain the impaired cytotoxic
activity in the peripheral blood during the first and second
trimester, although some publications suggest that this interaction
is not only limited to TIM-3 and that Gal-9 can also act on NK
cells independently of TIM-3 [25].
Several molecules modulate and influence the cells that are
directly involved in the generation and maintenance of an active
Figure 2. CD107a expression by peripheral blood mononuclear cell subsets throughout pregnancy and in non-pregnant women.
The expression of CD107a by TIM-3 negative and TIM-3 positive cytotoxic T cells and NK cells in the peripheral blood of normal pregnant women
during each trimester of pregnancy and in non-pregnant women. The solid bars represent medians, the boxes indicate the interquartile ranges and
the lines show the most extreme observations. Differences were considered statistically significant for P-values #0.05.
doi:10.1371/journal.pone.0092371.g002
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immunotolerance toward the fetus and accumulating evidence
points to galectins, a family of endogenous glycan-binding proteins
as an important regulator of pregnancy [26,27].
Gal-9 has complex immunomodulatory roles involving effector
cells of both innate and adaptive immunity [14,26,27]. This
important pleiotropic modulator affects numerous immune cell
types. In general, Gal-9 is thought to be involved in the activation
of innate immune responses [28,29] and the downregulation of
Th1 and Th17 responses [15,16,18]. Although a number of recent
papers have identified roles for Gal-9 in the inhibition of CD8+ T
cells, expansion of regulatory T cells, regulation of NK cell
function and promotion of Th2 cell migration, its role in
mediating immunotolerance during pregnancy is only now
emerging.
Gal-9 may regulate the immune function of NK cells and CD8+
T cells during pregnancy depending on the activation threshold,
stage of pregnancy, inflammatory stimuli, and relative expression
of cellular receptors.
The presence of Galectin-9 at the fetal-placental interface is
already known [20,21,30], and our study demonstrates for the first
time that Gal-9 is not only expressed by the placenta itself but also
by regulatory immune cells (Gal-9+ Th cells) in the peripheral
blood and it can be found at high concentration in the sera of
healthy pregnant women compared to non-pregnant women.
Analyzing serum Gal-9 levels throughout pregnancy we found an
increasing tendency with a significant elevation in the second and
third trimester compared to the first trimester, which correlates
with the emergence of Gal-9+ Th cells in the peripheral blood of
healthy pregnant women.
Since Oomizu et al. identified Gal-9+ Th cells in humans
secreting large amount of Gal-9 upon stimulation and regulate
Th17 development [18], we can suppose that this cell population
could be one of the populations to secrete Gal-9 found in the sera
of pregnant women.
A major unresolved issue is the exact role of Gal-9 in healthy
pregnancy. Given the demonstration that serum Gal-9 levels are
Figure 3. CD107a expression by peripheral blood mononuclear cell subsets throughout pregnancy and in non-pregnant women.
The expression of CD107a by TIM-3 negative and TIM-3 positive CD56dim and CD56bright cells in the peripheral blood of normal pregnant women
during each trimester of pregnancy and in non-pregnant women. The solid bars represent medians, the boxes indicate the interquartile ranges and
the lines show the most extreme observations. Differences were considered statistically significant for P-values #0.05.
doi:10.1371/journal.pone.0092371.g003
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significantly elevated throughout pregnancy compared to non-
pregnant women, it is tempting to hypothesize that one of the
primary function of this molecule is to support healthy pregnancy
suggesting that this physiological increase of Gal-9 during
pregnancy is presumably a counter-regulatory mechanism aimed
to regulate and control pro-inflammatory mechanisms during
pregnancy.
Based on our result we can hypothesize that Gal-9 influences
both CD8+ T and NK cells in the periphery of pregnant women
but in different ways.
We demonstrated that serum Gal-9 level is increased during
normal pregnancy, may result in decreased proinflammatory
cytokine production by TIM-3 positive CD8+ T cells and an
impaired cytotoxic activity by NK and NKdim cell expressing
TIM-3. TIM-3 is known to be involved in tolerance induction [17]
and now we can propose than TIM-3 cell surface molecule, widely
expressed on innate and adaptive immune cells could control the
immunoregulation during pregnancy.
Our results indicate that TIM-3 and Galectin-9 are able to
initiate different functional outcomes in a cell-specific manner
during pregnancy; however, further studies are needed to clarify
the exact role of TIM-3/Gal-9 pathway at the feto-maternal site.
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